Search hospitals > Ontario > BARRIE
SimcoDerm Medical and Surgical Dermatology Center
Claim this profileBARRIE, Ontario L4M 7G1
Global Leader in Psoriasis
Global Leader in Dermatitis
Conducts research for Medical Device Dermatitis
Conducts research for Atopic Dermatitis
Conducts research for Vitiligo
42 reported clinical trials
1 medical researcher
Summary
SimcoDerm Medical and Surgical Dermatology Center is a medical facility located in BARRIE, Ontario. This center is recognized for care of Psoriasis, Dermatitis, Medical Device Dermatitis, Atopic Dermatitis, Vitiligo and other specialties. SimcoDerm Medical and Surgical Dermatology Center is involved with conducting 42 clinical trials across 31 conditions. There are 1 research doctors associated with this hospital, such as Maryam Shayesteh Alam.Top PIs
Clinical Trials running at SimcoDerm Medical and Surgical Dermatology Center
Psoriasis
Atopic Dermatitis
Plaque Psoriasis
Dermatitis
Lichen Simplex Chronicus
Prurigo Nodularis
Prurigo
Eczema
Medical Device Dermatitis
ESK-001
for Plaque Psoriasis
The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are: * How safe is taking ESK-001 long-term in people with moderate to severe plaque psoriasis? * Does taking ESK-001 long-term reduce the severity of people's plaque psoriasis? Patients will enter the long-term extension study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-001 twice daily for 24 weeks. After 24 weeks, the first 200 patients meeting at least PASI-75 clinical response will be randomly assigned to receive ESK-001 or placebo. At any point during this time, the patients losing the initial clinical response may return to the open-label ESK-001 treatment. Patients who complete Week 48 will return to open-label ESK-001 treatment and they will receive ESK-001 until the end of the study or discontinuation. All the remaining patients not meeting the entry criteria for the randomized withdrawal phase will continue to receive open-label ESK-001 for the remainder of the study. Patients taking part in the study must be men or women aged at least 18 years old and have completed a previous (parent) study of ESK-001 in moderate to severe plaque psoriasis. Patients must consent and agree to: * ensure drug daily compliance until end of study or discontinuation. * visit the clinic for checkups and assessments. * provide blood and urine samples.
Recruiting1 award Phase 31 criteria
JNJ-77242113
for Plaque Psoriasis
The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.
Recruiting1 award Phase 35 criteria
LY4100511
for Psoriasis
The main purpose of this study is to assess the safety and efficacy of LY4100511 in adult participants with moderate-to-severe plaque psoriasis.
Recruiting0 awards Phase 21 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at SimcoDerm Medical and Surgical Dermatology Center?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.